Humacyte, Inc. HUMA
We take great care to ensure that the data presented and summarized in this overview for Humacyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HUMA
View all-
Black Rock Inc. New York, NY7.14MShares$10.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7MShares$10.3 Million0.0% of portfolio
-
State Street Corp Boston, MA4.39MShares$6.45 Million0.0% of portfolio
-
Center Book Partners LP Greenwich, CT3.43MShares$5.04 Million0.42% of portfolio
-
Geode Capital Management, LLC Boston, MA2.95MShares$4.33 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.64MShares$3.88 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.55MShares$3.75 Million0.0% of portfolio
-
Ubs Group Ag2.45MShares$3.59 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2MShares$2.94 Million0.02% of portfolio
-
Two Sigma Investments, LP New York, NY1.54MShares$2.26 Million0.01% of portfolio
Latest Institutional Activity in HUMA
Top Purchases
Top Sells
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Insider Transactions at HUMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2025
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
591,685
-100.0%
|
$591,685
$1.58 P/Share
|
|
Aug 20
2025
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
591,685
-100.0%
|
$591,685
$1.58 P/Share
|
|
Aug 19
2025
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
1,100,000
-65.02%
|
$1,100,000
$1.63 P/Share
|
|
Aug 19
2025
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
1,100,000
-65.02%
|
$1,100,000
$1.63 P/Share
|
|
Aug 18
2025
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
549,360
-24.51%
|
$549,360
$1.83 P/Share
|
|
Aug 18
2025
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
549,360
-24.51%
|
$549,360
$1.83 P/Share
|
|
Apr 14
2025
|
William John Scheessele Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
6,493
+22.77%
|
$6,493
$1.54 P/Share
|
|
Apr 10
2025
|
Shamik J Parikh Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
7,500
+50.0%
|
$7,500
$1.55 P/Share
|
|
Apr 10
2025
|
Dale A. Sander CFO and Chief Corp. Deve. Off. |
BUY
Open market or private purchase
|
Indirect |
20,000
+33.0%
|
$20,000
$1.53 P/Share
|
|
Apr 08
2025
|
Charles Bruce Green Director |
BUY
Open market or private purchase
|
Direct |
6,000
+41.67%
|
$6,000
$1.29 P/Share
|
|
Apr 08
2025
|
Kathleen Sebelius Director |
BUY
Open market or private purchase
|
Direct |
50,000
+35.41%
|
$50,000
$1.32 P/Share
|
|
Apr 07
2025
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
16,000
+32.69%
|
$16,000
$1.26 P/Share
|
|
Dec 04
2024
|
Michael T. Constantino Director |
BUY
Open market or private purchase
|
Direct |
4,600
+21.35%
|
$18,400
$4.39 P/Share
|
|
Nov 20
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
261,369
-13.12%
|
$1,045,476
$4.4 P/Share
|
|
Nov 20
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
261,369
-13.12%
|
$1,045,476
$4.4 P/Share
|
|
Nov 19
2024
|
Brady W Dougan Director |
BUY
Open market or private purchase
|
Indirect |
1,797
+0.73%
|
$7,188
$4.44 P/Share
|
|
Nov 19
2024
|
Laura E Niklason President, CEO and Director |
BUY
Open market or private purchase
|
Direct |
1,797
+0.73%
|
$7,188
$4.44 P/Share
|
|
Nov 19
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
427,459
-17.67%
|
$1,709,836
$4.34 P/Share
|
|
Nov 19
2024
|
Brady W Dougan Director |
SELL
Open market or private sale
|
Indirect |
427,459
-17.67%
|
$1,709,836
$4.34 P/Share
|
|
Nov 18
2024
|
Laura E Niklason President, CEO and Director |
SELL
Open market or private sale
|
Indirect |
811,172
-25.11%
|
$3,244,688
$4.44 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 114K shares |
|---|---|
| Exercise of conversion of derivative security | 1.2K shares |
| Open market or private sale | 7.48M shares |
|---|